Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia
- 7 March 2014
- journal article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 55 (9), 2120-2124
- https://doi.org/10.3109/10428194.2013.869328
Abstract
We herein evaluate the role of the B7-family molecule CD86 and the Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) as a possible immunopathogenic factors in patients with ALL. The results of 60 patients with de novo ALL were compared to 40 controls. A significant statistical difference between CD86 expression and sCTLA-4 levels in patients versus their controls has been detected. During follow up period of 28 months, patients suffered from relapse (16 patients) had significantly higher CD86 expression and sCTL-4 levels compared to those remained in complete remission (44 patients) (p = 0.005 and 0.03 respectively). Patients who died from the disease (9 patients) showed significantly higher CD 86 expression and sCTLA-4 levels than surviving patients (51 patients) (p = 0.004 and 0.01 respectively). In conclusion, the higher levels of sCTLA-4 and CD86 in B-ALL patients might be candidate parameters for poor prognosis and may serve to refine treatment stratification with intensification of therapy in those patients prone to relapse.Keywords
This publication has 28 references indexed in Scilit:
- A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ ExpressionPLOS ONE, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Immunotherapy prospects for acute myeloid leukaemiaClinical and Experimental Immunology, 2010
- Genetic Polymorphisms in Cytotoxic T-Lymphocyte Antigen 4 and Cancer: The Dialectical Nature of Subtle Human Immune DysregulationCancer Research, 2009
- Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01Blood, 2007
- Inhibitory Receptors CD85j, LAIR-1, and CD152 Down-Regulate Immunoglobulin and Cytokine Production by Human B LymphocytesClinical and Vaccine Immunology, 2005
- CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86Nature Immunology, 2004
- CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cellsBlood, 2002
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994